{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:46:30Z","timestamp":1761101190598},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T00:00:00Z","timestamp":1370390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00277-013-1797-y","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T11:47:48Z","timestamp":1370346468000},"page":"1503-1511","source":"Crossref","is-referenced-by-count":15,"title":["Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma"],"prefix":"10.1007","volume":"92","author":[{"given":"Simone","family":"Ferrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigia","family":"Monitillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mantoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Barbero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Barbiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Bernocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Caracciolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Drandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Zanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Renna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Lobetti Bodoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Gueli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Passera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,5]]},"reference":[{"key":"1797_CR1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","volume":"23","author":"WT Swenson","year":"2005","unstructured":"Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK (2005) Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019\u20135026","journal-title":"J Clin Oncol"},{"key":"1797_CR2","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","volume":"118","author":"R Griffiths","year":"2011","unstructured":"Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M (2011) Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 118:4808\u20134816","journal-title":"Blood"},{"key":"1797_CR3","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota SD, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL) (2008) Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004\u20134013","journal-title":"Blood"},{"key":"1797_CR4","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1200\/JCO.2009.22.6258","volume":"27","author":"L Goff","year":"2009","unstructured":"Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, Hagenbeek A, Morschhauser F, Putz B, Lister A, Rohatiner A (2009) Quantitative PCR analysis for Bcl-2\/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 27:6094\u20136100","journal-title":"J Clin Oncol"},{"key":"1797_CR5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","volume":"107","author":"C Pott","year":"2006","unstructured":"Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, Br\u00fcggemann M, Ritgen M, Gahn B, Unterhalt M, Dreyling M, Hiddemann W, Siebert R, Dreger P, Kneba M (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271\u20132278","journal-title":"Blood"},{"key":"1797_CR6","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH, Beldjord K, B\u00f6ttcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HC, Hermine O, Macintyre E, Dreyling M (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215\u20133223","journal-title":"Blood"},{"key":"1797_CR7","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","volume":"90","author":"NS Andersen","year":"1997","unstructured":"Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG (1997) Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 90:4212\u20134221","journal-title":"Blood"},{"key":"1797_CR8","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, Cuttica A, Rosato R, Farina L, Boccadoro M, Benedetti F, Pileri A, Tarella C (2004) Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 22:1460\u20131468","journal-title":"J Clin Oncol"},{"key":"1797_CR9","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"key":"1797_CR10","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE, Solomon E, Lo-Coco F, Wheatley K, Burnett AK (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27:3650\u20133658","journal-title":"J Clin Oncol"},{"key":"1797_CR11","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, K\u00f6hne-Volland R, Br\u00fcggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethm\u00fcller G, Hoelzer D, Zugmaier G, And Bargou RC (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29:2493\u20132498","journal-title":"J Clin Oncol"},{"key":"1797_CR12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordstr\u00f6m M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundstr\u00f6m C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687\u20132693","journal-title":"Blood"},{"key":"1797_CR13","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","volume":"27","author":"NS Andersen","year":"2009","unstructured":"Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordstr\u00f6m M, Fred\u00e9n S, Jerkeman M, Eriksson M, V\u00e4\u00e4rt J, Malmer B, Geisler CH (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 27:4365\u20134370","journal-title":"J Clin Oncol"},{"key":"1797_CR14","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/annonc\/mds202","volume":"23","author":"F Morschhauser","year":"2012","unstructured":"Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M (2012) A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol 23:2687\u20132695","journal-title":"Ann Oncol"},{"key":"1797_CR15","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","volume":"12","author":"M Ladetto","year":"2006","unstructured":"Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, Astolfi M, Matteucci P, Guidetti A, Mantoan B, Bodoni CL, Zanni M, Boccadoro M, Gianni AM, Tarella C (2006) Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 12:1270\u20131276","journal-title":"Biol Blood Marrow Transplant"},{"key":"1797_CR16","first-page":"171","volume-title":"World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 171\u2013174"},{"key":"1797_CR17","first-page":"233","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 233\u2013237","edition":"4"},{"key":"1797_CR18","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"1797_CR19","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","volume":"81","author":"JG Gribben","year":"1993","unstructured":"Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Spector N (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449\u20133457","journal-title":"Blood"},{"key":"1797_CR20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","volume":"89","author":"P Corradini","year":"1997","unstructured":"Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D, Pileri A, Tarella C (1997) Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin\u2019s lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 89:724\u2013731","journal-title":"Blood"},{"key":"1797_CR21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.exphem.2006.08.008","volume":"34","author":"M Ladetto","year":"2006","unstructured":"Ladetto M, Mantoan B, De Marco F, Drandi D, Aguzzi C, Astolfi M, Vallet S, Ricca I, Dell\u2019 Aquila M, Pagliano G, Monitillo L, Pollio B, Santo L, Cristiano C, Rocci A, Francese R, Bodoni CL, Borchiellini A, Schinco P, Boccadoro M, Tarella C (2006) Cells carrying nonlymphoma-associated bcl-2\/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. Exp Hematol 34:1680\u20131686","journal-title":"Exp Hematol"},{"key":"1797_CR22","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/sj.leu.2400801","volume":"11","author":"C Voena","year":"1997","unstructured":"Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M, Pileri A, Corradini P (1997) A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11:1793\u20131798","journal-title":"Leukemia"},{"key":"1797_CR23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0301-472X(03)00191-7","volume":"31","author":"M Ladetto","year":"2003","unstructured":"Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, dell\u2019Aquila M, Alfarano A, Rossatto P, Rocci A, Vitolo U, Corradini P, Boccadoro M, Tarella C (2003) Recurrence of Bcl-2\/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. Exp Hematol 31:784\u2013788","journal-title":"Exp Hematol"},{"key":"1797_CR24","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood.V95.8.2651","volume":"95","author":"JW Donovan","year":"2000","unstructured":"Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, Gribben JG (2000) Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 95:2651\u20132658","journal-title":"Blood"},{"key":"1797_CR25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","volume":"6","author":"M Ladetto","year":"2000","unstructured":"Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R, Anderson KC, Gribben JG (2000) Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 6:241\u2013253","journal-title":"Biol Blood Marrow Transplant"},{"key":"1797_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0301-472X(00)00651-2","volume":"29","author":"M Ladetto","year":"2001","unstructured":"Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, Ricca I, Drandi D, Corradini P, Coser P, Pileri A, Gribben JG, Tarella C (2001) A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol 29:183\u2013193","journal-title":"Exp Hematol"},{"key":"1797_CR27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH Velden van der","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ, European Study Group on MRD detection in ALL (ESG-MRD-ALL) (2007) Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604\u2013611","journal-title":"Leukemia"},{"key":"1797_CR28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2401737","volume":"14","author":"C Tarella","year":"2000","unstructured":"Tarella C, Caracciolo D, Corradini P, Zallio F, Ladetto M, Cuttica A, Rossi G, Novero D, Gavarotti P, Pileri A (2000) Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 14:740\u2013747","journal-title":"Leukemia"},{"key":"1797_CR29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","volume":"102","author":"AM Gianni","year":"2003","unstructured":"Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, Corradini P, Tarella C, Barbui T (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749\u2013755","journal-title":"Blood"},{"key":"1797_CR30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","volume":"29","author":"C Tarella","year":"2011","unstructured":"Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mul\u00e9 A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29:814\u2013824","journal-title":"J Clin Oncol"},{"key":"1797_CR31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferm\u00e9 C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42\u201351","journal-title":"Lancet"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1797-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1797-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1797-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T18:15:32Z","timestamp":1595873732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1797-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,5]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1797-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,5]]}}}